Meningococcal Vaccines Market Report by Vaccine Type (Conjugate, Polysaccharide, Subcapsular), Composition (Mono Vaccines, Combination Vaccines), Vaccine Serotype (MenACWY, MenB & Manic, MenC, MenA, MenAC, and Others), Distribution Channel (Hospital Pharm

Meningococcal Vaccines Market Report by Vaccine Type (Conjugate, Polysaccharide, Subcapsular), Composition (Mono Vaccines, Combination Vaccines), Vaccine Serotype (MenACWY, MenB & Manic, MenC, MenA, MenAC, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales, and Others), End User (Pediatric, Adult), and Region 2024-2032

The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032.

Meningococcal vaccine refers to a biological substance administered for the prevention of meningitis, which is a contagious infection of the membranes surrounding the spinal cord and the brain. The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines. They are administered to infants, children and adults to immunize them against the invasive disease and target meningococcal bacteria A, B, C, W-135 and Y. Once the vaccine is administered, antibodies are formed to fight the bacteria and create an immune response to prevent the infection in the future.

The increasing prevalence of the meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to the market growth. Meningococcal vaccine aids in preventing the disease and minimizing the long-term effects, such as temporary or permanent deafness, loss of vision and motor skills, seizure and neurological damage. In line with this, governments of both developed and emerging economies are launching extensive public health programs while emphasizing on the immunization of special risk groups, such as tourists and military personnel, to contain the risks of infections. Additionally, various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global meningococcal vaccines market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, composition, vaccine serotype, distribution channel and end user.

Breakup by Vaccine Type:

• Conjugate
• Polysaccharide
• Subcapsular

Breakup by Composition:

• Mono Vaccines
• Combination Vaccines

Breakup by Vaccine Serotype:

• MenACWY
• MenB & Manic
• MenC
• MenA
• MenAC
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• nstitutional Sales
• Others

Breakup by End User:

• Pediatric
• Adult

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Ltd. and Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report:

• How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global meningococcal vaccines market?
• What are the key regional markets?
• What is the breakup of the market based on the vaccine type?
• What is the breakup of the market based on the composition?
• What is the breakup of the market based on the vaccine serotype?
• What is the breakup of the market based on the distribution channel?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global meningococcal vaccines market and who are the key players?
• What is the degree of competition in the industry?